Nachrichten zur Astellas Pharma, Inc. Aktie

Pfizer, Astellas Xtandi significantly improves OS in phase 3 prostate cancer study

The phase 3 trial assessed Xtandi plus androgen deprivation therapy (ADT) against placebo plus ADT in men with non-metastatic castration-resistant…

Seattle Genetics, Astellas, and Merck Hit a Bladder Cancer Bullseye

Seattle Genetics posted eye-popping data from a study of patients given a combination of Padcev and Keytruda....…

Astellas files application in Japan for expanded use of roxadustat

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Astellas Submits Supplemental New Drug Application for Approval of Evrenzo® (roxadustat) for the Treatment of Anemia Associated with Chronic Kidney Disease in Non-Dialysis Dependent Patients in Japan

TOKYO and SAN FRANCISCO , Jan. 30, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE:…

BB Biotech lüftet das Geheimnis: Das ist der neue Wert im Portfolio

BB Biotech trennte sich im vieten Quartal 2019 von vier Beteiligungen und eröffnete eine neue Position. Audentes Therapeutics wurde von…

Astellas completes acquisition of Audentes Therapeutics

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Astellas Completes Acquisition of Audentes Therapeutics

TOKYO and SAN FRANCISCO , Jan. 15, 2020 /PRNewswire/ --…

Astellas, Adaptimmune sign deal to co-develop T-cell therapies for cancer

As per the terms of the deal, the Japanese pharma company and Adaptimmune will select up to three targets for…

Astellas Pharmas Xospata OKd in Canada for certain type of AML

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies

- Agreement covers the co-development and co-commercialization of up to three T-cell therapies -...…

Astellas Acquires Xyphos to Boost Immuno-oncology Pipeline

Astellas (ALPMY) acquires Xyphos and gains the latters novel and proprietary ACCEL technology platform....…

The Daily Biotech Pulse: Flexion Receives FDA Nod For Zilretta Label Expansion, Astellas Goes Shopping

The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks…

Astellas buys Xyphos to gain immuno-oncology platform, talent

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Astellas ramps up M&A, buys U.S. biotech Xyphos for as much as $665 million

Astellas Pharma Inc has bought U.S.-based Xyphos Biosciences Inc to expand its immuno-oncology business, a deal worth up to…

UPDATE 1-Astellas ramps up M&A, buys U.S. biotech Xyphos for as much as $665 mln

* Deal consists of $120 mln upfront, rest in milestone payments...…

Astellas Pharma buys Xyphos Biosciences, deal worth up to $665 mln

Astellas Pharma Inc has bought U.S.-based Xyphos Biosciences Inc to expand its immuno-oncology business, a deal worth up to $665 million including…

Astellas Strengthens Immuno-oncology Pipeline with Acquisition of Xyphos Biosciences, Inc.

TOKYO and SOUTH SAN FRANCISCO, Calif. , Dec. 26, 2019 …

Seattle Genetics stock rises on approval of bladder cancer drug

The Food and Drug Administration on Wednesday approved Padcev as a treatment for metastatic urothelial cancer. The therapy is jointly…

CORRECTED-FDA grants accelerated approval for Astellas, Seattle Genetics bladder cancer drug (Dec. 18)

U.S. Food and Drug Administration said on Wednesday it approved Astellas Pharma Inc and Seattle Genetics experimental drug to treat advanced bladder cancer,…

Seattle Genetics Drug For Difficult-To-Treat Urothelial Cancer Gets Early FDA Nod

Seattle Genetics, Inc. (NASDAQ: SGEN) shares are advancing following an early approval for Padcev, an antibody conjugate therapy it is…

Astellas, Seattle Genetics get FDAs accelerated approval for bladder cancer drug Padcev

Padcev, a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4 protein, has secured approval under the FDAs Accelerated Approval…

FDA grants accelerated approval for Astellas, Seattle Genetics bladder cancer drug

U.S. Food and Drug Administration said on Wednesday it approved Astellas Pharma Inc and Seattle Genetics experimental drug to treat advanced bladder cancer,…

Pfizer, Astellas secure expanded FDA approval for XTANDI

The latest approval means that XTANDI is indicated for the treatment of three distinct forms of advanced prostate cancer that…

FDA OKs expanded use of Astellas and Pfizers Xtandi

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

UPDATE 1-FDA approves expanded label for Pfizer, Astellas prostate cancer therapy Xtandi

The U.S. Food and Drug Administration has approved Pfizer Inc and Astellas Pharma Incs Xtandi to treat patients with a type of…

FDA approves expanded label for Pfizer, Astellas prostate cancer Xtandi

The U.S. Food and Drug Administration has approved Pfizer Inc and Astellas Pharma Incs Xtandi to treat patients with a type of…

Pfizer stock ticks higher on new FDA approval for prostate cancer drug

Pfizer Inc. shares ticked higher in the extended session Monday after the drug maker said the Food and Drug…

Pharmakonzern Astellas kauft für 3 Mrd Dollar US-Gentherapiespezialisten

Um den gesamten Artikel unter de.reuters.com zu lesen, klicken Sie bitte auf die Überschrift...…

Astellas and MBC BioLabs Announce Golden Ticket Winners - Supporting Biotech Start-Ups to Accelerate Innovative Science

MENLO PARK, Calif. , Dec. 5, 2019 /PRNewswire/ -- Astellas Venture Management (President: …

63 Biggest Movers From Yesterday

Gainers Audentes Therapeutics Inc (NASDAQ: BOLD) shares climbed 106% to close at $58.93 on Tuesday after the company agreed to be…

Pfizer/Astellas Xtandi Gets Nod in China for Prostate Cancer (Revised)

Pfizer (PFE)/Astellas Xtandi gets approval in China to treat metastatic castration-resistant prostate cancer (CRPC)....…

Biotechs second year of red-hot takeovers is set for a strong finish with Astellas Pharmas $3 billion buy and Novartiss $6.8 billion deal for Medicines Co.

Um den gesamten Artikel unter bloom.bg zu lesen, klicken Sie bitte auf die Überschrift...…

40 Stocks Moving In Tuesdays Mid-Day Session

Gainers Audentes Therapeutics Inc (NASDAQ: BOLD) shares jumped 105.9% to $58.90 after the company agreed to be acquired by Astellas Pharma…

The Gene Therapy Names Moving On The Audentes Buyout Deal

Gene therapy company Audentes Therapeutics Inc (NASDAQ: BOLD) announced a deal late Monday to be acquired by Japanese pharma company…

Audentes Therapeutics Soars on Astellas Pharmas $3 Billion Purchase

Um den gesamten Artikel unter thestreet.com zu lesen, klicken Sie bitte auf die Überschrift...…

Seattle Genetics, Astellas Tie Up With Merck for Cancer Study

Seattle Genetics (SGEN) and Astellas team up with Merck for a late-stage study to evaluate the enfortumab vedotin and Keytruda…

Japans Astellas To Buy Gene Therapy Company Audentes For $3B Cash

Another gene therapy name is likely to go under, with a trans-continental buyout deal announced by ASTELLAS PHARMA/ADR…

Audentes Therapeutics stock rockets 106% to record high after Astellas Pharma buyout deal

Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…

Kursexplosion - Offerte für Gentherapie-Spezialisten Audentes beflügelt Konkurrenten

Die drei Milliarden Dollar schwere Übernahmeofferte des japanischen Pharmakonzerns Astellas beschert Audentes den grössten Kurssprung der Firmengeschichte. Die Aktien stiegen…

Gene therapy stocks in focus after Astellas/Audentes deal

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Astellas bets $3 billion in gene therapy deal

Shares of Astellas Pharma Inc. rose about 1% in premarket trading after the Japanese drugmaker said Monday evening that…

The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial

The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks…

Astellas Presents New Data on XOSPATA® (gilteritinib) in FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia at the 2019 American Society of Hematology Annual Meeting

TOKYO , Dec. 2, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and…